MDACC Study No:2006-0478 ( NCT No: NCT00390793)
Title:Phase II study of combination of hyper-CVAD and dasatinib in patients with Philadelphia (Ph) chromosome positive and/or BCR-ABL positive acute lymphoblastic leukemia (ALL)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Adriamycin; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Methotrexate; Prednisone; Solumedrol; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if intensive
chemotherapy combined with dasatinib, followed by maintenance therapy, can help
to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this
treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Adriamycin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:approximately 4 or 5 days every 2 to 4 weeks. 21 to 28 days of hospitalization
if the induction course is carried in the protected environment
Supported By:N/A
Return Visit:Induction course will be administered at MD Anderson, thereafter patient visits
will occur every 2-4 courses.
Home Care:After the induction course all subsequent courses can be administered by local
oncologists under the instruction and prescription of MD Anderson physician or
PI of the study

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults